Overview
To compare transhiatal / transabdominal approach with thoracoabdominal approach for Siewert II adenocarcinoma of esophagogastric junction
Description
Objective: To compare the safety and clinical efficacy between transhiatal/transabdominal and thoracoabdominal approach for Siewert â…¡ adenocarcinoma of esophagogastric junction.
Methods: A prospective, multi-center, randomized, controlled study will be performed. Patients who meet the eligibility criteria will be registered in the study and undergo radical surgery via transhiatal/transabdominal or thoracoabdominal approach. The data of preoperative, intraoperative, postoperative and follow-up will be recorded and analyzed.
The primary endpoints :3-year disease-free survival. The secondary endpoints:(1) Surgery and oncology indicators ;(2) The incidences of postoperative complications and mortality.
Eligibility
Inclusion Criteria:
- 1.18~75 years old
- 2.The tumor center located at the esophagogastric junction(EGJ) line from 1cm above to 2cm below(Siewertâ…¡) .
- 3.Histological diagnosis of adenocarcinoma
- 4. American Society of Anesthesiologists(ASA) physical status class is less than or equal to 3
- 5.Informed consent of patients
Exclusion Criteria:
- 1.Patients with distant metastasis (M1) or invasion of surrounding organs
- 2.History of esophagectomy and gastrectomy (including endoscopic mucosal resection/endoscopic submucosal dissection for gastric cancer and esophageal cancer)
- 3.History of other malignant tumors within 5 years
- 4.The researcher believes that the patient is not suitable to participate in the clinical trial
- 5.Patients who persist in withdrawing from clinical trials